Solbinsiran

Phase 2RNA therapy

Eli Lilly

Solbinsiran is one of 45 small molecule programs targeting Severe Hypertriglyceridemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe HypertriglyceridemiaRecruiting

HypertriglyceridemiaActive, not recruiting

Severe HypertriglyceridemiaPhase 2

Recruiting

HypertriglyceridemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

63 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

Crestor

Cipro

Selzentry

Lopid

Zocor

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Zetia

Statin

1 9

EVKEEZA

Regeneron

Phase 2

2 10

Ciprofibrate

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Severe Hypertriglyceridemia

NCT07269210

Clinical

Trials by Indication[1]

Severe Hypertriglyceridemia1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07269210·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Solbinsiran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Solbinsiran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Solbinsiran. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

Solbinsiran

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Severe Hypertriglyceridemia1 trial

References

Drug Info

Quick Facts

Related News